CARBOGEN AMCIS, a Swiss pharmaceutical process development and manufacturing company owned by India-based Dishman Carbogen Amcis Limited, is investing more than CHF 25 million in partnership with a long-standing Japanese customer to expand manufacturing capacity at its Aarau and Neuland sites in Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC) and includes significant equipment and infrastructure upgrades at both locations.
At the Aarau site, the company plans to install 850-litre reactors and 0.4 square metre agitated filter dryers with supporting equipment. Completion is expected by the first quarter of 2027. At the Neuland site, similar equipment will be installed, with work scheduled for completion by the third quarter of 2027.
CARBOGEN AMCIS previously collaborated with the same Japanese customer in 2021 on a site extension at the company’s Bubendorf facility in Switzerland. The current investment builds on this earlier partnership and is aimed at strengthening the company’s manufacturing capabilities for highly potent compounds.
“By investing in both Aarau and Neuland, we’re ensuring that our infrastructure keeps pace with our customers’ ambitions. These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies,” said Carl Baker, Vice President Business Unit Drug Substance.
CARBOGEN AMCIS is part of Dishman Carbogen Amcis Limited, an Indian pharmaceutical outsourcing company headquartered in Ahmedabad. The parent company provides development, scale-up, and manufacturing services to the pharmaceutical industry through operations in Europe, India, and China.
